Our analysis of a second, clinically annotated breast cancer BM cohort showed that BM had a higher overall frequency of HER2-HER3 dimers compared to brain-metastatic primary tumours (particularly HER2+ cases, but not exclusively). This evidence concerns the gene ERBB2 and breast cancer.